CSIMarket
 


Lexaria Bioscience Corp   (LEXX)
Other Ticker:  
 

Lexaria Bioscience 's Long Term Debt to Equity

LEXX's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In the first quarter 2023 Lexaria Bioscience did not have Long Term Debt.

Within Major Pharmaceutical Preparations industry Lexaria Bioscience Corp achieved the lowest Long Term Debt to Equity in the first quarter 2023. While total ranking remained the same in the first quarter 2023 compared to the previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt LEXX´s has?
What is the structure of LEXX´s Equity?


LEXX Long Term Debt to Equity (Nov 30 2023)
I. Quarter
(Aug 31 2023)
IV. Quarter
(May 31 2023)
III. Quarter
(Feb 28 2023)
II. Quarter
(Nov 30 2022)
I. Quarter
Y / Y Equity Change -43.14 % -64.89 % -54.66 % - -48.28 %
Y / Y Long Term Debt Change - - - - -
Long Term Debt to Equity MRQ - - - - -
LEXX's Total Ranking # # # # #
Seq. Equity Change 25.84 % -33.68 % -12.75 % -21.92 % -22.28 %
Seq. Long Term Debt Change - - - - -



Long Term Debt to Equity first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Lexaria Bioscience 's Equity $ 3 Millions Visit LEXX's Balance sheet
Lexaria Bioscience 's Long Term Debt $ 0 Millions Visit LEXX's Balance sheet
Source of LEXX's Sales Visit LEXX's Sales by Geography


Cumulative Lexaria Bioscience 's Long Term Debt to Equity

LEXX's Long Term Debt to Equity for the trailling 12 Months

LEXX Long Term Debt to Equity

(Nov 30 2023)
I. Quarter
(Aug 31 2023)
IV. Quarter
(May 31 2023)
III. Quarter
(Feb 28 2023)
II. Quarter
(Nov 30 2022)
I. Quarter
Y / Y Equity TTM Growth -43.14 % -64.89 % -54.66 % - -48.28 %
Y / Y Long Term Debt TTM Growth - - - - -
Long Term Debt to Equity TTM - - - - -
Total Ranking TTM
Seq. Equity TTM Growth 25.84 % -33.68 % -12.75 % -21.92 % -22.28 %
Seq. Long Term Debt TTM Growth - - - - -


On the trailing twelve months basis During the twelve months ending I Quarter 2023 Lexaria Bioscience did not have Long Term Debt .
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry LEXX recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt LEXX´s has?
What is the structure of LEXX´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Nov 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityNov 30 2023 MRQ Long Term DebtNov 30 2023 MRQ Equity

Date modified: 2024-01-14T10:22:20+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com